| Document |
Document Title |
|
WO/2014/052382A1 |
Polymers containing natural oil derivatives are generally disclosed. Methods of forming such polymers are also generally disclosed. In some embodiments, the polymer is a polyurethane. In some embodiments, the natural oil derivative is a ...
|
|
WO/2014/033604A1 |
The present invention provides arylalkylamine compounds as calcium sensing receptor modulators (CaSR). In particular, the compounds described herein are useful for treating, managing, and/or lessening the severity of diseases, disorders,...
|
|
WO/2014/028487A1 |
Provided herein are lipidoids that may be prepared from the conjugate addition of alkylamines to acrylates. In some embodiments, provided lipidoids are biodegradable and may be used in a variety of drug delivery systems. Given the amino ...
|
|
WO/2014/027473A1 |
Provided is a stable isotope-labeled aliphatic amino acid that makes possible the assignment of the signal of an amino acid residue side chain by raising to the maximum the observation sensitivity of the NMR signal of the same amino acid...
|
|
WO/2014/025708A1 |
Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).
|
|
WO/2014/025709A1 |
Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).
|
|
WO/2014/020866A1 |
[Problem] To provide a method for producing a basic amino acid or a basic amino acid salt each suitable for various use applications including medical applications, industrial applications, feed applications and food additive application...
|
|
WO/2014/020164A1 |
The invention relates to new derivatives of 5-aminolevulinic acid (5-ALA) and their use as photosensitizing agents. In particular, it relates to compounds of general formula I and their pharmaceutically acceptable salts, to methods for p...
|
|
WO/2014/013104A1 |
The invention relates to a method for identifying compounds that are potentially useful for the treatment of sporadic amyotrophic lateral sclerosis (ALS), comprising the use of an animal model of rats, developed by means of the administr...
|
|
WO/2014/012371A1 |
Disclosed are aromatic spiroketal diphosphine ligands, preparation methods and uses thereof. The ligands have the structure of formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, X and n are defined as such described in the specificati...
|
|
WO/2014/012935A1 |
The present application relates to novel substituted aminoindane- and aminotetralincarboxylic acids, to processes for preparation thereof, to the use thereof for treatment and/or prevention of diseases and to the use thereof for producti...
|
|
WO/2014/012372A1 |
A process for the production of ezetimibe and intermediates used in said process are disclosed. A kind of Morita-Baylis-Hillman adduct can be altered to carboxylic acid derivatives of β-arylamino α-methylene with high activity and sele...
|
|
WO/2014/009025A1 |
The invention relates to novel methods for synthesizing a synthon for γ,δ- dihydroxyisoleucine 1 (CAS No. 55399-94-5] as building block for the synthesis of amatoxins, and for novel methods for synthesizing amatoxins using such buildin...
|
|
WO/2014/006625A1 |
The present invention relates to the compound amino-phenyl-acetic acid octadec- (Z)-9-enyl ester, an enantiomer thereof or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising it, for use in the treatment...
|
|
WO/2014/003969A1 |
Provided are compounds for use as neutralizing agents in aqueous formulations. The compounds are of the formula I: (Formula I should be inserted here.) wherein R, R1, R2, R3, R4, and R5 are as defined herein.
|
|
WO/2013/183490A1 |
The present invention provides a long-life, high-capacity lithium secondary cell intended to improve cycle characteristics and suppress a reduction in capacity particularly when used in high-temperature environments. A lithium secondary ...
|
|
WO/2013/182023A1 |
The present invention provides a carbon fiber surface modifier, a modified carbon fiber, composites, and preparation methods therefor. The general structural formula of the carbon fiber surface modifier is as represented by formula (I): ...
|
|
WO/2013/181741A1 |
The present invention relates to compounds having the general Formula I: which absorb UV radiations and protect biological materials as well as non-biological materials from damaging exposure to UV radiations. The present invention also ...
|
|
WO/2013/178810A1 |
The invention relates to novel compounds, derivatives of ornithine or of lysine, to pharmaceutical compositions containing same and to the use of same in the treatment of pain.
|
|
WO/2013/180271A1 |
Provided are a fluorine-containing amino acid prodrug represented by general formula (I) that makes a fluorine-containing amino acid which is a group 2 metabotropic glutamate receptor agonist into a prodrug, or a pharmacologically accept...
|
|
WO/2013/174916A1 |
Compounds particularly for use in an autoimmune inflammatory disease and especially the treatment of inflammatory bowel disease have the absolute stereochemistry and formula (I). In some cases R1 is leucine and R is selected from: OH, OC...
|
|
WO/2013/172239A1 |
The present invention is an acid diffusion control agent consisting of at least one compound selected from among the group consisting of a compound represented by formula (1) and a compound represented by formula (2). In formula (1), R2 ...
|
|
WO/2013/168019A1 |
The invention relates to the compounds of formula (I), formula (II), formula (III) and formula (IV) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceuti...
|
|
WO/2013/168010A1 |
Compounds or their pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I), and methods...
|
|
WO/2013/168780A1 |
Provided is a method for producing an optically active 1-amino-2-vinylcyclopropane-1-carboxylic acid ester and 2-vinylcyclopropane-1,1-dicarboxylic acid ester, which do not isomerize during a reaction, with an inexpensive and easily obta...
|
|
WO/2013/169531A1 |
This invention relates to methods for making oxetan-3-ylmethanamines having the formula (I) wherein R1? and R2? are as defined herein. The methods of the invention provide the compounds of formula (I) in high yields and under conditions ...
|
|
WO/2013/164416A1 |
The invention relates to an organometallic complex of the amino acid/metal type. The complex is a crystalline pluri-metal complex that can be obtained in the form of a homogeneous powder that can be used to optimise animal feed. More spe...
|
|
WO/2013/158579A1 |
The instant invention provides for novel cationic lipids of Formula A that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of th...
|
|
WO/2013/157528A1 |
Provided is a medicinal agent comprising a compound represented by general formula (1), a pharmaceutically acceptable salt of the compound or a solvate of the compound or the pharmaceutically acceptable salt. A compound represented by ge...
|
|
WO/2013/156341A1 |
The present invention relates to novel bifunctional branched and unsaturated compounds of formula (I), obtained from fatty acids. The invention also relates to a method for preparing same and to the uses thereof, in particular as monomer...
|
|
WO/2013/158127A1 |
New cationic lipids are provided that are useful for delivering macromolecules, such as nucleic acids, into eukaryotic cells. The lipids can be used alone, in combination with other lipids and/or in combination with other transfection en...
|
|
WO/2013/154066A1 |
The problem addressed by the present invention is to efficiently produce an optically active bicyclic compound. The present invention efficiently produces an optically active bicyclic compound using an enzyme.
|
|
WO/2013/144500A1 |
The invention relates to a method for synthesizing ivabradine of formula (I) and its addition salts with a pharmaceutically acceptable acid.
|
|
WO/2013/148554A1 |
This invention relates to a resolution process for the preparation of fluoroleucine alkyl esters.
|
|
WO/2013/148550A1 |
The instant invention describes a novel asymmetric synthesis of fluoroleucine alkyl esters which utilizes allylation of a glycine derivative containing an imine moiety in the presence of a phase transfer catalyst and a solid additive, fo...
|
|
WO/2013/139143A1 |
Disclosed is a salfaprodil crystal form I, belonging to a triclinic system. A space group is P1(1); cell parameters: a=7.5286(13)Å, b=7.5754(12)Å, c=28.2018(13)Å, α=82.54(1)º, β=83.48(1)º, γ=84.16(2)º, and Z=2; the cell volume V...
|
|
WO/2013/136030A2 |
The present invention relates to powder compositions of a complex between an acid and a metal and to the method for preparing same.
|
|
WO/2013/137330A1 |
Provided is a method for producing optically active 1-amino-2-vinylcyclopropane-1-carboxylic acid ester and 2-vinylcyclopropane-1,1-dicarboxylic acid ester, which use an optically active material that can be cheaply and easily obtained a...
|
|
WO/2013/130968A1 |
Provided are compounds according to the following Formula (I). The Formula (I) compounds are activated in the presence of reactive oxygen species (ROS) and are therefore selective anti-cancer therapeutics for cancers associated with elev...
|
|
WO/2013/129682A1 |
Provided is a production method in which a compound comprising an amino group and/or a hydroxyl group is generated under mild conditions by removing atom groups containing CO or CS from a substrate compound containing such atom groups. A...
|
|
WO/2013/126803A1 |
The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel, trialkyl, cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation ...
|
|
WO/2013/126428A1 |
The present invention relates to novel phenoxy derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1- phosphate receptors. Formula (I)
|
|
WO/2013/122028A1 |
The purpose of the present invention is to provide an aromatic ring compound exhibiting GPR40 agonist activity. The compound represented by formula (I) (refer to the description for information pertaining to each symbol in the formula) o...
|
|
WO/2013/118823A1 |
The purpose of the present invention is to provide: a novel method for producing cereulide and a derivative thereof; an intermediate for cereulide; and a novel cereulide derivative. A novel didepsipeptide, a novel tetradepsipeptide, a no...
|
|
WO/2013/114991A1 |
The purpose of the present invention is to obtain an amino acid that has 2-7 carbon atoms and is useful as a synthesis intermediate of a pharmaceutical or agricultural chemical, as a high-purity solid, simply and efficiently without a co...
|
|
WO/2013/116174A1 |
The present invention provides novel mGlu2/3 agonists of formula (I) useful in the treatment of neurological or psychiatric disorders.
|
|
WO/2013/110374A1 |
The absorption of CO2 from a gas mixture by bringing the gas mixture in contact with an absorption medium, which contains water and 5 to 50 wt% of amino acid salts of the formula R1R2CHNHCH2COOK, wherein R1 and R2 are n-alkyl groups and ...
|
|
WO/2013/107587A1 |
A compound obtained by reaction of one or more amines of the general formula NHR6R7 with a compound of the following general formula (IX), wherein - PI is a photoinitiator derivative, - G is linker comprising a number p' of unreacted hyd...
|
|
WO/2013/107588A1 |
A compound obtained by reaction of one or more amines of general formula NHR6R7 with a benzophenone derivative of the following general formula (IX) wherein M is a group comprising a number z of (meth)acrylate groups equal to at least L ...
|
|
WO/2013/105117A1 |
Invention provides a cheaper and practical protocol for the construction of a wide variety of 1-Amino-2-naphthalenecarboxylic acid derivatives and their structural analogues that proceeds with high yields in a single step via intramolecu...
|
